MN Community Measurement and the Endocrine Society (ES) are pleased to announce the completion of measure specifications for a suite of new measures aimed at improving the health outcomes and reducing modifiable risks for patients with obesity. The Specifications Engineering Group (SEG) and Technical Expert Panel (TEP) meetings concluded in October 2021 with the recommendation to proceed with obtaining public comment on four measures currently under consideration prior to the pilot testing phase.

• Obesity Prediabetes and Diabetes HbA1c Control
• Obesity Weight Loss with Medication
• Obesity Diagnosis
• Obesity Blood Pressure Control

The committee previewed preliminary results from the 2020 measurement year (2020 dates of service) and provided additional input on the factors that may have contributed to the difference in measurement outcomes for care delivered in 2020 as a result of the COVID-19 pandemic. Additionally, MNCM will be releasing a special spotlight report as well as individual measure briefs in early August, which will summarize and display the impact of COVID-19 on quality measurement for care delivered in 2020.

Comments may be submitted at publiccomment@mncm.org no later than Friday, December 17, 2021.

Obesity Prediabetes and Diabetes HbA1c Control

The percentage of patients 12 to 75 years of age with a diagnosis of type 2 diabetes or prediabetes and whose most recent BMI is ≥ 27/BMI Percentile ≥ 95 during the measurement period. HbA1c target for patients with a diagnosis of prediabetes is less than 6.5. HbA1c target for patients with a diagnosis of type 2 diabetes is less than 8.0. View detail: Obesity Prediabetes and Diabetes A1c Control Measure.

Obesity Weight Loss with Medication

The percentage of adult patients 18 years of age and older whose most recent BMI is ≥ 30 or BMI ≥ 27 and comorbidities* or Asian descent and initiate a weight loss medication during the denominator identification period who have a weight loss of greater than or equal to 10% within six months (-30/+ 60 days). View detail: Obesity Weight Loss with Medication Measure.

* comorbidities of prediabetes, metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea and nonalcoholic fatty liver disease.

 

Obesity Diagnosis

The percentage of adult patients 18 years of age and older whose most recent BMI is ≥ 30 or ≥ 27 with comorbidities* or Asian descent and children ages 2 to 17 whose most recent BMI percentile ≥ 95 during the measurement period and have the diagnosis of obesity active on their problem list. View detail: Obesity Diagnosis Measure.

* comorbidities of prediabetes, metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea and nonalcoholic fatty liver disease.

Obesity Blood Pressure Control

The percentage of adult patients 18 to 85 years of age whose most recent BMI is ≥ 30 or ≥ 27 with comorbidities* or Asian descent whose most recent blood pressure during the measurement period is less than 140 systolic and less than 90 diastolic. View detail: Obesity Blood Pressure Control Measure.

* comorbidities of prediabetes, metabolic syndrome, type 2 diabetes, dyslipidemia, hypertension, obstructive sleep apnea and nonalcoholic fatty liver disease.